Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
DexCom, Inc. - Common Stock
(NQ:
DXCM
)
61.63
+3.81 (+6.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about DexCom, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
↗
Today 9:08 EDT
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and...
Via
MarketBeat
What's going on in today's session: S&P500 movers
↗
May 15, 2026
Via
Chartmill
Uncover the latest developments among S&P500 stocks in today's session.
↗
May 15, 2026
Via
Chartmill
Sell in May and Go Away—Starting With These 3 Stocks
↗
May 12, 2026
Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.
Via
MarketBeat
Topics
Artificial Intelligence
These S&P500 stocks have an unusual volume in today's session
↗
May 01, 2026
Via
Chartmill
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals
↗
May 01, 2026
Via
Chartmill
DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Drop
↗
April 30, 2026
Via
Chartmill
2 Mid-Cap Stocks with Impressive Fundamentals and 1 We Question
May 12, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via
StockStory
3 Quality Compounders Worth Your Attention
May 08, 2026
Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr...
Via
StockStory
5 Insightful Analyst Questions From DexCom’s Q1 Earnings Call
May 07, 2026
DexCom’s first quarter saw revenue growth driven by new product launches and increased adoption, particularly among people with type 2 diabetes who are not o...
Via
StockStory
Topics
Earnings
Economy
3 Reasons Analysts Love DexCom
↗
May 05, 2026
Via
MarketBeat
DEXCOM INC (NASDAQ:DXCM) Shows Strong Fundamentals and a Promising Technical Breakout Setup
↗
April 24, 2026
Via
Chartmill
Friday's session: gap up and gap down stock in the S&P500 index
↗
May 01, 2026
Via
Chartmill
What's going on in today's pre-market session: S&P500 movers
↗
May 01, 2026
Via
Chartmill
DXCM Q1 Deep Dive: U.S. Growth Moderates as Product Momentum and Coverage Expansion Drive Strategy
May 01, 2026
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 15% year on year to $1.19 bil...
Via
StockStory
2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
May 01, 2026
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Via
StockStory
DexCom (DXCM) Q1 2026 Earnings Transcript
↗
April 30, 2026
DexCom (DXCM) Q1 2026 Earnings Transcript
Via
The Motley Fool
Top S&P500 movers in Thursday's after hours session
↗
April 30, 2026
Via
Chartmill
DexCom (NASDAQ:DXCM) Exceeds Q1 CY2026 Expectations But Stock Drops
April 30, 2026
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 15% year on year to $1.19 b...
Via
StockStory
2026 Market Cap Madness Championship: Loren v. Emily
↗
April 29, 2026
It’s time to crown a winner: defending champion Emily Flippen faces off against Cinderella challenger Loren Horst in the Market Cap Madness World Championship.
Via
The Motley Fool
DexCom (DXCM) Q1 Earnings: What To Expect
April 28, 2026
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market close. Here’s what investors should know. DexCom beat analy...
Via
StockStory
Topics
Artificial Intelligence
1 Cash-Producing Stock to Target This Week and 2 Facing Challenges
April 24, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
↗
April 23, 2026
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.
Via
The Motley Fool
Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom
↗
April 20, 2026
They offer investors very different value propositions.
Via
The Motley Fool
2 Healthcare Stocks That Could Outperform the Market Over the Next Decade
↗
April 16, 2026
Both have helped transform their respective industries.
Via
The Motley Fool
3 Reasons Investors Love DexCom (DXCM)
April 16, 2026
Over the last six months, DexCom’s shares have sunk to $62.07, producing a disappointing 6.4% loss - a stark contrast to the S&P 500’s 5.1% gain. This may ha...
Via
StockStory
Topics
Stocks
Explore the top gainers and losers within the S&P500 index in today's session.
↗
April 13, 2026
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via
Chartmill
Q4 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
April 12, 2026
Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. Patient ...
Via
StockStory
Topics
Artificial Intelligence
DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy
↗
April 10, 2026
DexCom (DXCM) exemplifies GARP investing, offering strong growth in glucose monitoring at a price reasonable relative to its industry and supported by robust profitability.
Via
Chartmill
DexCom (DXCM) Q2 2025 Earnings Call Transcript
↗
April 08, 2026
DexCom (DXCM) Q2 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit